Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 2004

View Archived Issues

Tarceva accepted onto FDA Pilot 1 Program

Xenon Genetics changes name to Xenon Pharmaceuticals

Large Scale Biology and the U. of Louisville collaborate on HPV-associated cancers

Phase Ic results of PYY3-36 nasal spray for obesity

Alcon files second portion of Retaane rolling NDA

Enrollment under way in two phase III Leukine studies for Crohn's disease

New phase II study of Telcyta combination front-line treatment of NSCLC

Merck & Co. and Alnylam collaborate on RNAi therapeutics for ocular diseases

BioXell acquires from Roche rights to new indications for BXL-628

Eisai launches Apnission in Japan

Acetylcholinesterase inhibitor ITH-4012 shows calcium promoting and neuroprotective activity

Centocor and Fujisawa discontinue codevelopment of abciximab in Japan

CoTherix submits NDA for Ventavis

OPi and Vaccinex establish antibody collaboration

European orphan drug designation recommended for Surfaxin

Striant SR submitted for mutual recognition procedure in Europe

Mitsubishi Pharma describes series of cyclic amide derivatives

COX-2 inhibitors presented by CJ Corporation

Achillion Pharmaceuticals claims inhibitors of hepatitis C virus replication

Ubiquitination inhibitors in early development at Rigel

BMS scientists prepare and test novel selective androgen receptor modulators

Sumitomo discloses agents for fibrosis in patent literature

Modafinil beneficial in patients with schizophrenia

Development of LJP-1082 and LJP-394 reviewed

Novel potent and selective T-type calcium channel blockers

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026